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Abstract
Objectives: To assess the efficacy and safety of a treat-
ment switch from a twice-daily (BID) regimen con-
taining zidovudine (ZDV) and lamivudine (3TC) plus
a third agent to a once daily (QD) regimen containing
the fixed-dose combination of tenofovir DF/emtri-
citabine (TDF/FTC, Truvadaﾮ) plus a divergent third
QD agent in HIV-1 infected patients.
Methods: Prospective, 48-week, non-randomised, sin-
gle-group, open-label, study. Fifty-one patients on sta-
ble ZDV/3TC-containing HAART, with HIV-1 RNA
<50 copies/ml and CD4+ T-cell count >50 cells/ﾵl,
were switched to TDF/FTC plus a third agent. Plasma
HIV-1 RNA, CD4+ and CD8+ T-cell counts were as-
sessed at baseline and weeks 4, 12, 24, 36 and 48 post-
switch.
Results: During the 48-week study, 10 patients discon-
tinued prematurely, including three due to adverse
events (AEs). At week 48, plasma HIV-1 RNA was
<50 copies/ml in 40 patients (78.4%). No patient ex-
perienced virological failure (defined as HIV-1 RNA
≥50 copies/ml at two consecutive post-baseline mea-
surements) during the study. Immunologic control was
maintained, with no significant changes in CD4+ or
CD8+ T-cell counts. A statistically significant im-
provement from baseline in haemoglobin level was
observed at week 48 (median change 0.8 g/dl;
p<0.001). There was also a statistically significant de-
crease in total cholesterol concentration at week 48
(-26.0 mg/dl; p = 0.001) in a subset of patients (n =
22) entering the study with elevated total cholesterol.
Treatment was well tolerated and no treatment-related
grade 3 or 4 AEs were seen.
Conclusions: Results from this study support switching
from a ZDV/3TC-containing HAART regimen to a
completely QD regimen of TDF/FTC plus a third
agent. Virologic and immunologic control are main-
tained, with apparent benefits in haemoglobin.
Key words: HAART; tenofovir DF; emtricitabine; com-
bination therapy; once-daily
INTRODUCTION
The goal of antiretroviral therapy (ART) in type 1
HIV (HIV-1) is to maintain health and well-being with
minimum drug side effects [1]. This is usually achieved
by suppressing viral replication below detectable levels
for as long as possible. In addition, keeping the viral
titre at low levels helps to prevent the development of
resistant viral strains [1]. Advances in therapy, such as
the introduction of highly active ART (HAART), have
greatly improved the prognoses of patients infected
with HIV [2-4]. HAART typically includes a combina-
tion of three antiretroviral agents, including two nu-
cleos(t)ide reverse transcriptase inhibitors (NR-
TIs/NtRTIs) with a non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) or a protease inhibitor (PI),
which together are able to suppress HIV-1 to below
detectable levels [1].
Despite the introduction of HAART, treatment is
currently unable to completely eradicate HIV-1 [5, 6].
Therefore, successful, long-term efficacy is greatly de-
pendent on patient adherence to the prescribed
HAART regimen. Good adherence increases the likeli-
hood of sustained virological control and reduces
HIV-1-related morbidity and mortality, while poor ad-
herence can lead to periods of viral replication and
possible development of resistance to one or more of
the drugs [7]. Therefore, the use of simplified, prefer-
ably once daily regimens with a low pill burden may be
able to improve adherence [8, 9, 10, 11].
At initiation of the present study, first-line HIV-1
treatment for most patients in Germany was fixed-
dose ZDV/3TC complemented by an NNRTI or a
boosted PI. Trials using this regimen have demonstrat-
ed successful viral suppression in addition to sustained
increases in CD4+ T-cell counts, which restored some
level of immune function to patients with HIV-1 in-
fection [12]. However, the ZDV/3TC combination
has limitations: it must be dosed twice daily (BID) due
to the short half-life of ZDV and, while 3TC shows
good tolerability, ZDV is known to cause a number of
adverse effects, such as anaemia, fatigue and nausea
[12]. Medication side effects including metabolic and
morphological changes with HAART are one of the
factors associated with poor adherence and shorter
durability of first-line HAART [10, 13, 14].
There is a clinical need for potent regimens that
simplify adherence through once daily (QD) dosing,
offer good tolerability and fit into the daily life of pa-
tients living with HIV-1 infection. The fixed-dose
combination of emtricitabine/tenofovir DF (Truva-
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of a completely QD regimen. At the time this trial was
started, the fixed dose combination of TDF/FTC was
not yet licensed in the European Union, and data on
the possibility of switching patients on stable HAART
to TDF/FTC did not exist. This Phase III proof of
concept study was designed to address the question of
whether patients receiving a stable ZDV/3TC contain-
ing regimen can be switched to a completely QD
TDF/FTC-containing regimen.
PATIENTS AND METHODS
This prospective, single-group, open-label, 48-week,
study enrolled 52 patients (one patient was excluded
due to a high baseline HIV-1 RNA concentration). All
patients had HIV-1 infection and were on a stable
ZDV/3TC-containing BID regimen for at least the
previous 3 months, with full viral suppression (HIV-1
RNA <50 copies/ml) and CD4+ T-cell counts >50
cells/ﾵl. Viral load was determined locally to avoid
screening failures, which may occur when switching the
diagnostic system and to compare historical values
with values during the study in patients with virologic
failure. Patients were selected for the study if they were
experiencing side effects (38% of patients), if it was
deemed they would benefit from a QD regimen (50%)
or both (12%). Patients were mainly male (92%), with
median age of 40.0 years (range 19-69 years), mean
body mass index of 23.6 kg/m2 and mean duration on
a ZDV/3TC-containing regimen of 3.75 years.
The protocol was approved by the appropriate ethi-
cal committees and all patients signed an informed
consent form. At baseline, patients switched from
their current BID regimen to a QD regimen contain-
ing TDF/FTC and a third QD agent. The third agent
was efavirenz for 30 (58%) patients, nevirapine for 13
(25%), a boosted protease inhibitor for 7 (13%) and
abacavir (recorded as a protocol violation) for 2 (4%)
patients. Divergent HAART was mandatory, i.e. the
third drug had to be from the NNRTI or PI antiretro-
viral classes. Patients were assessed at baseline and
weeks 4, 12, 24, 36 and 48. For patients withdrawn
prematurely, a discontinuation visit took place as soon
as possible.
HIV-1 RNA concentrations were measured using
reverse transcriptase PCR (Roche Amplicor HIV-1
Monitor or COBAS AmpliPrep/COBAS TaqMan
HIV-1 test). The primary endpoint was the proportion
of patients who maintained the target HIV-1 RNA
concentration of <50 copies/ml at week 48, consis-
tent with guidelines for viral suppression. Secondary
endpoints included proportion of patients with HIV-1
RNA <50 copies/ml by study visit and changes in
CD4+ and CD8+ T-cell counts. Virological failure
was defined as HIV-1 RNA ≥50 copies/ml for two
consecutive post-baseline measurements. Safety in-
cluded adverse event (AE) reporting and laboratory
assessments. Serum creatinine concentration was used
to estimate glomerular filtration rate and creatinine
clearance by the Cockcroft-Gault method. Quality of
Life was assessed by SF-12 Health Survey at baseline
and weeks 12, 24 and 48.
The primary analysis used an approach where any
missing value was considered to be a treatment failure.
Secondary analyses used approaches including missing
= excluded and early discontinuation = failure. Statis-
tical significance of changes from baseline was as-
sessed using Wilcoxon signed rank tests.
RESULTS
The full 48 weeks of treatment was completed by
41/51 (80.4%) patients. Early discontinuations were
due to AE/intercurrent illness in three cases, protocol
violation in three cases, patient decision in two cases,
loss to follow-up in one case and non-compliance in
one case.
At week 48, plasma HIV-1 RNA was <50
copies/ml for 78% of patients (40/51) using the miss-
ing = failure approach. Using the missing = excluded
approach, the 40 patients translated to 98% (40/41 pa-
tients). Numbers of patients with HIV-1 RNA <50
copies/ml at each time point are shown in Table 1 by
reason for switching to the TDF/FTC plus third agent
QD regimen. There were no obvious differences be-
tween reasons for switching treatment. HIV-1 RNA
>50 copies/ml at any time was observed for two pa-
tients at week 24, who had switched therapy to simpli-
fy the regimen and had HIV-1 RNA concentrations of
50 and 59 copies/ml (both stayed on therapy and
HIV-1 RNA was re-suppressed), and for one patient at
week 48 (HIV-1 RNA = 254 copies/ml) who had
switched due to side effects. No patient experienced
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Table 1. Numbers of patients with plasma HIV-1 RNA concentration <50 copies/ml at each study visit, by reason for switch to
TDF/FTC (n (%)).
Reason for switch of therapy
Side effects* (N = 19) Simplify regimen (N = 26) Both (N = 6) Total (N = 51)
Week 4 18 (95) 25 (96) 5 (83) 48 (94)
Week 12 19 (100) 23 (88) 5 (83) 47 (92)
Week 24 19 (100) 20 (77) 4 (67) 43 (84)
Week 36 18 (95) 18 (69) 3 (50) 39 (76)
Week 48 15 (79) 21 (81) 4 (67) 40 (78)
* Side effects most commonly reported were: gastrointestinal disorders (n = 12), lipodystrophy (n = 7) and anaemia (n = 3)
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surements of HIV1-RNA > 50 copies/ml) during the
study.
There were no statistically significant changes from
baseline in CD4+ and CD8+ T-cell counts throughout
the study (Table 2). At baseline, five patients had
CD4+ T-cell counts ≤200 cell/ﾵl, of whom one was
lost to follow-up immediately after and four had an in-
crease in CD4+ T-cell count to >200 cells/ﾵl by week
48. At week 48, all patients with available data had
CD4+ T-cell counts >200 cells/ﾵl.
Laboratory tests indicated a statistically significant
(p<0.001) increase in haemoglobin levels at week
48 (Table 2). There was no apparent effect on renal
function, measured by creatinine clearance at week
48. While there was no difference in total cholesterol
or HDL looking at the median values in all treated pa-
tients, there was a statistically significant (p = 0.001)
decrease in fasting total cholesterol concentration at
48 weeks in patients with total cholesterol ≥200
mg/dl at baseline. Grade 3 toxicity elevations of
alanine aminotransferase were reported for two pa-
tients and grade 4 increase in asparate aminotrans-
ferase for one patient, and grade 3 or 4 decreases in
blood glucose were seen in two patients. None of the
grade 3/4 toxicities were considered related to treat-
ment.
Treatment-emergent AEs were reported for 45/52
patients (87%), with the most frequent being na-
sopharyngitis (60%), diarrhoea (13%) and gastroen-
teritis (10%). Most were deemed unrelated to treat-
ment and only 13 AEs in seven patients were consi-
dered treatment-related by the study investigators
(Table 3). Serious AEs were reported for three pa-
tients but were classified as unrelated to treatment (in-
guinal hernia, hepatic failure and depression). AEs re-
sulted in discontinuation for three patients, of which
two were considered related to treatment (renal pain
and drug hypersensitivity).
No statistically significant changes from baseline in
SF-12 (Version 1) physical or mental composite scores
were reported during the study, Scores for these
HIV infected subjects were similar to the general pop-
ulation, i.e., with mean scores of approximately
50.
DISCUSSION
Despite the availability of potent antiretroviral thera-
pies, many patients with HIV-1 infection are still un-
able to achieve or maintain adequate suppression of
viral load , often because of incomplete adherence to
the treatment regimen [7, 9, 10, 11]. Total pill burden,
dosing frequency and safety concerns have been iden-
tified as specific obstacles to achieving adherence [8, 9,
10, 11].
Switching regimens is a standard means of main-
taining suppression of viral load and supporting im-
mune function over time, particularly when the switch
is to a simpler regimen [15, 16]. However, every switch
bears a risk of failure or changes in tolerability. In the
present study, patients switched from a BID regimen
to an entirely QD regimen. There were no cases of
confirmed virological failure, defined as two consecu-
tive HIV-1 RNA measurements ≥50 copies/ml, and
therefore, no testing for virological resistance was per-
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Table 2. Change from baseline in T-cell counts and laboratory results at week 48; values are medians with interquartile ranges.
Baseline Change to week 48 p-value*
CD4+ count (cells/ﾵl) 526 (317 : 774) 30 (-72 : 125) 0.23
CD8+ count (cells/ﾵl) 907 (664 : 1209) -80 (-263 : 91) 0.16
Haemoglobin (g/dl) 14.8 (14.1 : 15.3) 0.8 (0.3 : 1.3) <0.001
Fasting total cholesterol (mg/dl) 194.0 (167 : 225) -5.0 (-32 : +17) 0.203
Fasting total cholesterol (mg/dl) 240.5 (222 : 251) -26.0 (-39 : -4) 0.001
in patients with baseline values
≥ 200 mg/dl (n = 22)
Fasting HDL (mg/dl) 50.5 (44 : 59) 52 (44 : 59) 0.094
Creatinine clearance (ml/min) 114 (97 : 127) -1.3 (-13.9 : 8.1) 0.20
* p-value for change from baseline using Wilcoxon signed rank test
Table 3. Treatment-emergent adverse events related to TDF/
FTC (none of these events were Grade 3 or 4).
n%
Number of patients experiencing any adverse 7 13%
event related to TDF/FTC
Cardiac disorder (palpitation) 1 2%
Gastrointestinal disorders (flatulence, faeces
discoloured) 2 4%
Drug Hypersensitivity 1 2%
Increased Amylase 1 2%
Increased Creatine phosphokinase 1 2%
Lactic Acid increased 1 2%
Increased Lipase 1 2%
Arthralgia 1 2%
Nervous System Disorders (Dizziness, 1 2%
paraesthesia)
Renal pain 1 2%
Rash 1 2%
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agent was well tolerated in this study population and
most AEs were considered unrelated to the study regi-
men. In the ITT analysis, viral load was maintained be-
low 50 copies in 78% of patients at week 48. Ten pa-
tients discontinued the trial prematurely, two due to
adverse events considered related to the study drug,
and eight for other reasons (protocol violation, con-
sent withdrawal, loss to follow up, non-compliance).
This number may have been influenced by the fact
that the fixed dose combination of TDF/FTC was li-
censed and commercially introduced during the study
period.
Laboratory tests revealed an improvement in
haemoglobin levels following the switch to a QD regi-
men of TDF/FTC plus a third agent. This possibly
reflected the change from a ZDV-containing therapy,
which has been reported to cause anaemia [17]; how-
ever, no patients were anaemic at baseline in this study.
Previous studies have demonstrated an association be-
tween increased haemoglobin levels, even within the
normal range, and improved energy and quality of life
in AIDS patients [18]. HAART has been shown to
produce dyslipidaemia in HIV-1 infected patients [19].
The present pilot study demonstrated a decrease in
fasting total cholesterol after 48 weeks of switching
from a ZDV/3TC-containing BID regimen to a
TDF/FTC containing QD regimen in patients with
elevated values at baseline. Additional information on
changes in total cholesterol, HDL, LDL and trigly-
cerides is available from the COMET study in which
patients were switched from ZDV/3TC+EFV to
TDF/FTC+ EFV [20],. The results from this study
showed statistically significant declines in all four para-
meters between baseline and week 24.
There are some important limitations associated
with this trial. The first and most obvious is the lack of
a control group. The present study was designed as a
proof of concept study to address whether it would
be safe to switch virologically stable patients from
ZDV/3TC to TDF/FTC, which was at that time not
yet licensed in Europe. As such, SONETT enrolled
only a relatively small number of patients and did not
include any comparator treatment. However, compari-
son with baseline values indicated that patients who
switched from a ZDV/3TC-containing BID regimen
to a QD regimen of TDF/FTC plus a third QD agent
maintained virologic suppression and immunologic
function over the 48 week treatment period. In the
meantime, results from an open-label, randomized
switch trial (SWEET) [21] have been published, which
show similar findings to those reported in SONETT.
The benefits of switching from a BID to a QD re-
gimen could not be fully evaluated, as these patients,
who had been successfully treated with a ZDV/3TC-
containing regimen for a median of 3.75 years, were
adherent to their regimen. This may, together with the
small numbers of patients, also explain the lack of a
difference in quality of life between baseline and week
48. Some information on the possible benefits of
switching to a complete QD regimen can be derived
from COMET, which enrolled 402 patients: treatment
satisfaction and absence of side effects changed signi-
ficantly (p<0.001) between baseline and week 24 [20].
In summary, the results from the present pilot study
support switching from a BID ZDV/3TC-containing
regimen to a completely QD regimen of TDF/FTC
plus a third agent. The results show maintained viro-
logic and immunologic control consistent with similar
switching strategies examined in the COMET and
SWEET studies [20, 21]. TDF/FTC QD plus third
agent regimen also appears to provide benefits in im-
proved haemoglobin and total cholesterol profiles.
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